Insulin-Like Growth Factor Binding Protein-5 Human Recombinant
库存:
大量
供应商:
上海经科化学科技有限公司
CAS号:
无
规格:
5μg/25μg/1mg
重组人胰岛素样生长因子结合蛋白-5(IGFBP5)相关产品:
CYR61 Human IGFBP 1 Human IGFBP 3 Human IGFBP 4 Human IGFBP 5 Human IGFBP 6 Human IGFBP3 Human, His IGFBP6 (28-240) Human IGFBP7 Human IGFBP7 Human, His NOV Mouse
重组人胰岛素样生长因子结合蛋白-5(IGFBP 5)说明书:
Insulin-Like Growth Factor Binding Protein-5 Human Recombinant:
Catalogue Number
CYT-464
Synonyms
IGFBP-5, IBP-5, IGF-binding protein 5.
Introduction
IGFBP5 is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
Description
IGFBP5 Human Recombinant produced in E.Coli is a single, non-glycosylated, homodimeric polypeptide chain containing 252 amino acids and having a molecular mass of 28.6 kDa. IGFBP5 is purified by proprietary chromatographic techniques.
Source
Escherichia Coli.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
IBP-5 was lyophilized from a concentrated (1mg/ml) solution containing 10mM sodium Citrate pH-3
Solubility
It is recommended to reconstitute the lyophilized Insulin-Like Growth Factor Binding Protein-5 in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
Stability
Lyophilized IBP5 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IGFBP 5 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.
Purity
Greater than 98.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
The ED50, calculated by its ability to inhibit IGF-II induced proliferation of MCF-7. The expected ED50 for this effect is < 0.4 ?g/ml, corresponding to a specific activity of > 2500 IU/mg in the presence of 15 ng/ml of rHuIGF-II.